Wednesday, July 8, 2026

biotech · Hypertension · Essential Hypertension · QNTM

Quantum Pharmaceuticals

Quantum Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

volkova 6A-1206, Moscow, 141700, RU, CA HQ
2004 Founded
29 Employees
Public company Type
QNTM · NYSE Ticker
Company details
Status
Public
HQ
volkova 6A-1206, Moscow, 141700, RU, CA
Founded
2004
Employees
29
Programs
18
Drugs
17
Patents
36
Intelligence · Clinical Programs

Quantum Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Quantum Pharmaceuticals.

Quantum Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Firibastat

    Quantum Biopharma

    Hypertension

    phase 3 small molecule completed

    1 trial
  2. Firibastat (QGC001) Period 1

    Quantum Biopharma

    Hypertension (HTN)

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Quantum Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.